MicroRNA regulation of lymphocyte tolerance and autoimmunity

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2242-2249

  Simpson, Laura J ^a   Ansel, K Mark ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL FATE; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; ANIMAL; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTES; MICE; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84930396449     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78090     Document Type: Article

References (95)

1. Ohashi PS. T-cell signalling and autoimmunity: Molecular mechanisms of disease. Nat Rev Immunol. 2002;2(6): 427-438.
2. Hasler P, Zouali M. B cell receptor signaling and autoimmunity. FASEB J. 2001;15(12): 2085-2098.
3. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annu Rev Immunol. 2012;30: 531-564.
4. Iikuni N, Lourenço EV, Hahn BH, La Cava A. Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol. 2009;183(3): 1518-1522.
5. Kozomara A, Griffiths-Jones S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013;42(D1): D68-D73.
6. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8): 509-524.
7. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136(2): 215-233.
8. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol. 2013;13(9): 666-678.
9. O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012;30: 295-312.
10. Xiao C, Rajewsky K. MicroRNA control in the immune system: Basic principles. Cell. 2009;136(1): 26-36.
11. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3-4): 189-194.
12. Junker A, Hohlfeld R, Meinl E. The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol. 2011;7(1): 56-59.
13. Filková M, Jüngel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: Potential role in diagnosis and therapy. BioDrugs. 2012;26(3): 131-141.
14. Koralov SB, et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008;132(5): 860-874.
15. Ventura A, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008;132(5): 875-886.
16. Xiao C, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4): 405-414.
17. Li QJ, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;129(1): 147-161.
18. Henao-Mejia J, et al. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity. 2013;38(5): 984-997.
19. Ebert PJ, Jiang S, Xie J, Li QJ, Davis MM. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol. 2009;10(11): 1162-1169.
20. Papadopoulou AS, et al. The thymic epithelial microRNA network elevates the threshold for infection-Associated thymic involution via miR-29a mediated suppression of the IFN-A receptor. Nat Immunol. 2012;13(2): 181-187.
21. Ucar O, Tykocinski LO, Dooley J, Liston A, Kyewski B. An evolutionarily conserved mutual interdependence between Aire and microRNAs in promiscuous gene expression. Eur J Immunol. 2013;43(7): 1769-1778.
22. Khan IS, Taniguchi RT, Fasano KJ, Anderson MS, Jeker LT. Canonical microRNAs in thymic epithelial cells promote central tolerance. Eur J Immunol. 2014;44(5): 1313-1319.
23. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197: 179-191.
24. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol. 2009;9(11): 767-777.
25. Belver L, de Yébenes VG, Ramiro AR. MicroRNAs prevent the generation of autoreactive antibodies. Immunity. 2010;33(5): 713-722.
26. Mraz M, et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 124(1): 84-95.
27. Rao DS, O'Connell RM, Chaudhuri AA, Garcia- Flores Y, Geiger TL, Baltimore D. MicroRNA- 34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity. 2010;33(1): 48-59.
28. Berry GJ, Budgeon LR, Cooper TK, Christensen ND, Waldner H. The type 1 diabetes resistance locus B10 Idd9.3mediates impaired B-cell lymphopoiesis and implicates microRNA- 34a in diabetes protection. Eur J Immunol. 2014;44(6): 1716-1727.
29. Khan AA, Penny LA, Yuzefpolskiy Y, Sarkar S, Kalia V. MicroRNA-1792 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections. Blood. 2013;121(22): 4473-4483.
30. Baumjohann D, et al. The microRNA cluster miR-17~92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013;14(8): 840-848.
31. Simpson LJ, et al. A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production. Nat Immunol. 2014;15(12): 1162-1170.
32. Kang SG, et al. MicroRNAs of the miR-17~92 family are critical regulators of T(FH) differentiation. Nat Immunol. 2013;14(8): 849-857.
33. Palacios F, et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia. 2015;29(1): 115-125.
34. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/- mice. Science. 1999;285(5436): 2122-2125.
35. Wu XN, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med. 2014;6(246): 246ra99.
36. Wei B, Pei G. microRNAs: Critical regulators in Th17 cells and players in diseases. Cell Mol Immunol. 2010;7(3): 175-181.
37. O'Connell RM, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33(4): 607-619.
38. Blüml S, et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011;63(5): 1281-1288.
39. Escobar TM, et al. miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity. 2014;40(6): 865-879.
40. Wang H, et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol. 2014;15(4): 393-401.
41. Mok Y, et al. MiR-210 is induced by Oct-2, regulates B cells, and inhibits autoantibody production. J Immunol. 2013;191(6): 3037-3048.
42. Liu SQ, Jiang S, Li C, Zhang B, Li QJ. miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Finger 4 to promote TH17-mediated inflammation. J Biol Chem. 2014;289(18): 12446-12456.
43. Zhu E, et al. miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting ROR?t and STAT3. J Immunol. 2014;192(12): 5599-5609.
44. Zhou X, et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008;205(9): 1983-1991.
45. Liston A, Lu LF, O'Carroll D, Tarakhovsky A, Rudensky AY. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med. 2008;205(9): 1993-2004.
46. Chong MM, Rasmussen JP, Rudensky AY, Rundensky AY, Littman DR. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med. 2008;205(9): 2005-2017.
47. Lu LF, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30(1): 80-91.
48. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol. 2009;182(5): 2578-2582.
49. Jiang S, et al. Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood. 2011;118(20): 5487-5497.
50. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013;191(4): 1594-1605.
51. Takahashi H, et al. TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol. 2012;13(6): 587-595.
52. Jeker LT, et al. MicroRNA 10a marks regulatory T cells. PLoS One. 2012;7(5): E36684.
53. Warth SC, et al. Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation [published online ahead of print February 23, 2015]. EMBO J. doi: 10.15252/embj.201489589.
54. Marcais A, et al. microRNA-mediated regulation of mTOR complex components facilitates discrimination between activation and anergy in CD4 T cells. J Exp Med. 2014;211(11): 2281-2295.
55. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30: 39-68.
56. Borlado LR, et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 2000;14(7): 895-903.
57. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med. 2008;205(3): 565-574.
58. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. Cutting edge: Deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-β sensitivity in vitro and in vivo. J Immunol. 2006;176(3): 1316-1320.
59. Sauer S, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A. 2008;105(22): 7797-7802.
60. Merkenschlager M, Boehmer von H. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J Exp Med. 2010;207(7): 1347-1350.
61. Bachmaier K, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature. 2000;403(6766): 211-216.
62. Okoye IS, et al. MicroRNA-containing T-regulatory- cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity. 2014;41(1): 89-103.
63. Bryniarski K, et al. Antigen-specific, antibodycoated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol. 2013;132(1): 170-181.
64. Singh RP, et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013;12(12): 1160-1165.
65. Lashine YA, Salah S, Aboelenein HR, Abdelaziz AI. Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus. 2015;24(3): 240-247.
66. Tang Y, et al. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60(4): 1065-1075.
67. Fu L, et al. Comprehensive review of genetic association studies and meta-Analysis on miRNA poly- morphisms and rheumatoid arthritis and systemic lupus erythematosus susceptibility [published online ahead of print: September 11, 2014]. Hum Immunol. doi: 10.1016/j.humimm.2014.09.002.
68. Luo X, et al. A functional variant in microRNA- 146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011;7(6): E1002128.
69. Otaegui D, et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One. 2009;4(7): E6309.
70. Fenoglio C, et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011;504(1): 9-12.
71. Keller A, et al. Multiple sclerosis: MicroRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One. 2009;4(10): E7440.
72. Cox MB, et al. MicroRNAs miR-17 and miR- 20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One. 2010;5(8): E12132.
73. Zhang J, et al. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;266(1-2): 56-63.
74. Du C, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12): 1252-1259.
75. Sebastiani G, et al. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev. 2011;27(8): 862-866.
76. Lindberg RLP, Hoffmann F, Mehling M, Kuhle J, Kappos L. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol. 2010;40(3): 888-898.
77. Pan W, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010;184(12): 6773-6781.
78. Fulci V, et al. miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol. 2010;71(2): 206-211.
79. Lu MC, et al. Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1- mediated interleukin-10 production. Clin Exp Immunol. 2014;177(3): 641-651.
80. Martínez-Ramos R, et al. Differential expression pattern of microRNAs in CD4+ and CD19+ cells from asymptomatic patients with systemic lupus erythematosus. Lupus. 2014;23(4): 353-359.
81. De Santis G, et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol. 2010;226(1-2): 165-171.
82. Smigielska-Czepiel K, et al. Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes Immun. 2014;15(2): 115-125.
83. Hezova R, et al. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 2010;260(2): 70-74.
84. Seumois G, et al. An integrated nano-scale approach to profile miRNAs in limited clinical samples. Am J Clin Exp Immunol. 2012;1(2): 70-89.
85. Li J, et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(3): R81.
86. Guo Q, et al. Forced miR-146a expression causes autoimmune lymphoproliferative syndrome in mice via downregulation of Fas in germinal center B cells. Blood. 2013;121(24): 4875-4883.
87. Chan EK, Ceribelli A, Satoh M. MicroRNA-146a in autoimmunity and innate immune responses. Ann Rheum Dis. 2013;72(suppl 2): Ii90-ii95.
88. Solberg OD, et al. Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med. 2012;186(10): 965-974.
89. Kurowska-Stolarska M, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A. 2011;108(27): 11193-11198.
90. Ceribelli A, Satoh M, Chan EK. MicroRNAs and autoimmunity. Curr Opin Immunol. 2012;24(6): 686-691.
91. Janssen HL, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18): 1685-1694.
92. Murugaiyan G, et al. MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J Clin Invest. 2015;125(3): 1069-1080.
93. Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A. 2009;106(44): 18704-18709.
94. Murugaiyan G, Beynon V, Mittal A, Joller N, Weiner HL. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2011;187(5): 2213-2221.
95. Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J. 2012;6: 245-258.